KIT and adrenal cortex carcinoma: We have previously used it in combination with imatinib and achieved a complete metabolic response in c-Kit and phospho-NF-κB-positive metastatic ACC [23], as both proteins are highly expressed and associated with disease progression in patients with ACC [64,65].